Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015, 159(3):460-465 | DOI: 10.5507/bp.2014.013

Recurrent salivary pleomorphic adenoma shows increased immunohistologic expression of bcl-2 oncoprotein

Katarina Obtulovicovaa, Ivo Starekb, Richard Salzmanb, Adrian Kalisc, Jiri Ehrmannd, Marian Sicaka, Jana Dvorackovae
a Clinic of Otorhinolaryngology and Head and Neck Surgery, Central Military Hospital and Faculty Hospital, Ruzomberok, Slovak Republic
b Clinic of Otorhinolaryngology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
c Institute of Pathology, Central Military Hospital and Faculty Hospital, Ruzomberok, Slovak Republic
d Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc
e Department of Pathology, University Hospital Ostrava

Background: Internal cell biology, including apoptotic regulation, is presumed to play a key role in the development of recurrent pleomorphic adenoma (PA).

Aim: The aim of our study was to determine the relevance of B-cell lymphoma 2 (bcl-2) oncoprotein immunoexpression and distribution in primary PA, and its recurrence.

Methods: Ten primary-non-recurrent, 14 primary-to-recur, and 28 recurrences of parotid PA patients aged 19-73 (mean 40.7±16.7) years were enrolled. The bcl-2 expression was compared between groups using a semi-quantitative histoscore, defined as the multiple of the percentage of cells by the intensity of immunostaining.

Results: Widely varying bcl-2 immunoreaction was found in the epithelial areas of 91.7% of primary and 85.2% of recurrent PA. Similarly varying but much less, immunopositivity was found in the myxoid areas of 62.5% of primary and 71.4% of recurrent tumours. No obvious differences in the bcl-2 staining intensity or pattern of specific epithelial morphologic structures in either the primary-non-recurrent, primary-to-recur or recurrent tumours were found. In both the mesenchymal and epithelial areas of PA, the differences in bcl-2 immunohistoscore between the primary-non-recurrent and primary-to-recur groups were not statistically significant (P=0.62, respectively 0.51). In the mesenchymal areas, the study revealed a significantly increased histoscore in recurrent tumours compared to their corresponding primaries (P=0.01). Increased bcl-2 expression in recurrent PA suggests an exaggerated aggressiveness of that tumor.

Conclusion: The fact that a significant difference in the histoscore was found exclusively in the myxoid component seems to accord with the reported prevalence of the latter in recurrent and metastatic PA.

Keywords: apoptosis, bcl-2 gene, recurrence, pleomorphic adenoma, mesenchymal stromal cells

Received: September 17, 2013; Accepted: February 27, 2014; Prepublished online: March 14, 2014; Published: September 30, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Obtulovicova, K., Starek, I., Salzman, R., Kalis, A., Ehrmann, J., Sicak, M., & Dvorackova, J. (2015). Recurrent salivary pleomorphic adenoma shows increased immunohistologic expression of bcl-2 oncoprotein. Biomedical papers159(3), 460-465. doi: 10.5507/bp.2014.013
Download citation

References

  1. Mehle ME, Kraus DH, Wood BG, Benninger MS, Eliachar I, Levine HL, Tucker HM, Lavertu P. Facial nerve morbidity following parotid surgery for benign disease: The cleveland clinic foundation experience. Laryngoscope 1993;103(4):386-8. Go to original source... Go to PubMed...
  2. Niparko JK, Beauchamp ML, Krause ChJ, Baker SR, Work WP. Surgical Treatment of Recurrent Pleomorphic Adenoma of the Parotid Gland. Arch Otolaryngol Head Neck Surg 1986;112(11):1180-4. Go to original source... Go to PubMed...
  3. Barnes L, Eveson JW, Reichard P, Sidransky D (Eds). World Health Organisation Classification of Tumors. Pathology and Genetics of Head and Neck Tumours. IARC Press: Lyon 2005.
  4. Stennert E, Wittekindt C, Kluddmann JP, Klussmann JP, Arnold G, Guntinas-Lichius O. Recurrent pleomorphic adenoma of the parotid gland: a prospective histopathological and immunohistochemical study. Laryngoscope 2004;114:1580-643. Go to original source... Go to PubMed...
  5. Witt RL. The significance of the margin in parotid surgery for pleomorphic adenoma. Laryngoscope 2002;112:2141-5. Go to original source... Go to PubMed...
  6. Ghosh S, Panarese A, Bull PD, Lee JA. Marginally excised parotid pleomorphic salivary adenomas: risk factors for recurrence and management. A 12.5 year mean follow-up study of histologically marginal excisions. Clin Otolaryngol All Sci 2003;28:262-6. Go to original source... Go to PubMed...
  7. Buchman C, Stringer SP, Mendenhall WM, Parsons JT, Jordan JR, Cassisi NJ. Pleomorphic adenoma: effect of tumour spill and inadequate resection on tumor recurrence. Laryngoscope 1994;104:1231-4. Go to original source... Go to PubMed...
  8. Foote FW, Frazell EL. Tumors of the major salivary glands. Cancer 1953;7:1065-133. Go to original source... Go to PubMed...
  9. McGregor AD, Burgyone M, Tan KC. Recurrent pleomorphic salivary adenoma - the relevance of age at first presentation. Br J Plast Surg 1988;41:177-81. Go to original source... Go to PubMed...
  10. Naeim F. Mixed tumors of the salivary glands: growth patterns and recurrence. Arch Pathol Lab Med 1976;100:271-5.
  11. Zbaren P, Stauffer E. Pleomorphic adenoma of the parotid gland: Histopathologic analysis of the capsular characteristics of 218 tumors. Head Neck 2007;29:751-7. Go to original source... Go to PubMed...
  12. Goudot P, Auriol M, Chomette G, Vaillant JM, Guilbert F. Pleomorphic adenoma of salivary glands. Incidence of myxoid component as a prognostic marker. Rev Stomatol Chir Maxillofac 1989;90:119-22. Go to PubMed...
  13. Skálová A, Walter J, Stárek I, Michal M. Proliferative activity in pleomorphic adenoma: prediction of the recurrency. Čes Stomat 2006;106(1):27-32.
  14. Laccourreye H, Laccourreye O, Cauchois R, Jouffre V, Ménard M, Brasnu D. Total conservative parotidectomy for primary benign pleomorphic adenoma of the parotid gland: a 25-year experience with 229 patients. Laryngoscope 1994;104(12):1487-94. Go to original source... Go to PubMed...
  15. Natvig K, Soberg R. Relationship of intraoperative rupture of pleomorphic adenomas to recurrence: an 11-25 year follow-up study. Head Neck 1994;16(3):213-7. Go to original source... Go to PubMed...
  16. Fee WE, Goffinet RD, Calcaterra TC. Recurrent mixed tumor of the parotid gland. Arch Otolaryngol 1984;110:167-71. Go to original source... Go to PubMed...
  17. Bradley PJ. Recurrent salivary gland pleomorphic adenoma: etiology, management and results. Curr Opin Otolaryngol Head Neck Surg 2001;9:100-8. Go to original source...
  18. Antonsson B, Martinou JC. The Bcl-2 protein family. Exp Cell Res 2000;191:50-57. Go to original source... Go to PubMed...
  19. Yanez M, Roa I, Garcia M. Bcl-2 protein expression in salivary gland tumors. Rev Med Chil 1999;127:139-42. Go to PubMed...
  20. Aoki T, Tsuninoki K, Karakida K, Ota Y, Otsuru M, Kaneko A. Expression of cyclooxygenase-2, Bcl-2 and Ki-67 in pleomorphic adenoma with special reference to tumor proliferation and apoptosis. Oral Oncol 2004;40:954-9. Go to original source... Go to PubMed...
  21. Soini Y, Tormanen U, Paakko P. Apoptosis is inversely related to bcl-2 but not to bax expression in salivary gland tumours. Histopathol 1998;32(1):28-34. Go to original source... Go to PubMed...
  22. Cruz Perez DE, Pires FR, Alves FA, Almeida OP, Kowalski LP. Salivary gland tumors in children and adolescents: a clinicopathologic and immunohistochemical study of fifty-three cases. Int J Ped Otorhinolaryngol 2004;68:895-902. Go to original source... Go to PubMed...
  23. Pammer J, Horvath R, Weninger W, Ulrich W. Expression of bcl-2 in salivary glands and salivary gland adenomas. A contribution to the reserve cell theory. Path Res Pract 1995;191:35-41. Go to original source... Go to PubMed...
  24. Debiec-Rychter M, van Valckenborgh I, van den Broeck C, Hagemeijer A, Van de Ven WJM, Kas K, Van Damme B, Voz ML. Histologic localization of PLAG1 (pleomorphic adenoma gene 1) in pleomorphic adenoma of the salivary gland: cytogenetic evidence of common origin of phenotypically diverse cells. Lab Invest 2001;81:1289-97. Go to original source... Go to PubMed...
  25. Gordon-Nunez MA, Godoy GP, Soares RC. Immunohistochemical expression of PCNA, p53 and bcl-2 in pleomorphic adenomas. Int J Morphol 2008;26:567-72. Go to original source...
  26. Al-Rawi NH, Omer H, Al-Kawas S. Immunohistochemical analysis of P53 and bcl-2 in benign and malignant salivary gland tumors. J Oral Pathol Med 2010;39:48-55. Go to original source... Go to PubMed...
  27. Sunardhi-Widyaputra S, van Damme B. Immunohistochemical pattern of Bcl-2 and PTHrP-positive cells in primary, in recurrent and in carcinoma in pleomorphic adenomas. Path Resp Pract 1995;191:1186-91. Go to original source...
  28. Tovey SM, Dunne B, Witton CJ, Cooke TG, Bartlett JMS. HER4 in breast cancer: comparison of antibodies against intra- and extracelullar domains in HER4. Breast Cancer Research 2006;8:19. Go to original source... Go to PubMed...
  29. Seifert G, Miehlke A, Haubrich J. Pathology, diagnosis, treatment, facial nerve surgery. In: Seifert G. Diseases of the salivary gland. Stuttgart, New York: Thieme; 1987. p. 171.
  30. Eversole LR. Histogenic classification of salivary gland tumors. Arch Pathol 1971;92:433-43.
  31. Dardick I, van Nostrand AWP, Phillips MJ. Histogenesis of salivary gland pleomorphic adenoma (mixed tumor) with an evaluation of the role of the myoepithelial cell. Hum Pathol 1982;13;62-75. Go to original source... Go to PubMed...
  32. Bradley PJ. "Metastasizing pleomorphic salivary adenoma" should now be considered a low-grade malignancy with a lethal potential. Curr Opinion in Otolaryngol Head Neck Surg 2005;13:123-6. Go to original source...
  33. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers in prostate carcinoma. Am J Clin Pathol 1998;110(4):443-9. Go to original source... Go to PubMed...
  34. Chatla C, Jhala NC, Katkoori VR, Alexander D, Meleth S, Grizzle WE, Manne U. Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma. 1994;Am J Pathol 1(4-5):241-50. Go to original source...
  35. Joensuu H, Pylkkänen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145(5):1191-8.
  36. Manjunatha BS, Kumar GS, Raghunath V. Immunohistochemical expression of Bcl-2 in benign and malignant salivary gland tumors. Med Oral Patol Oral Cir Bucal 2011;16(4):503-7. Go to original source... Go to PubMed...
  37. Norberg-Spaak L, Dardick I, Ledin T. Adenoid cystic carcinoma: use of cell proliferation, Bcl-2 expression, histologic grade, and clinical stage as predictors of clinical outcome. Head Neck 2000;22:(5):489-97. Go to original source... Go to PubMed...
  38. Carlinfante G, Lazzaretti M, Ferrari S, Bianchi B, Crafa P. p53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. Pathol Res Pract 2005;200:791-9. Go to original source... Go to PubMed...
  39. Andreadis D, Epivatianos A, Mireas G, Nomikos A,  Poulopoulos A, Yiotakis J, Barbatis C. Immunohistochemical detection od E-cadherin in certain types of salivary gland tumours. J Laryngol Otol 2006;120:298-304. Go to original source... Go to PubMed...
  40. Brieger J, Duesterfoeft A, Brochhausen Ch, Gosepath J, Kirkpatrick CJ, Mann WJ. Recurrence of pleomorfic adenoma of the parotid gland - predictive value of cadherin-11 and fascin. J Comp 2008;116:1050-7. Go to original source...
  41. Bankamp DG, Bierhoff E. Proliferation markers in primary and secundary salivary pleomorphic adenoma. Laryngo Rhino Otol 1999;78:77-80. Go to original source... Go to PubMed...
  42. Martin AR, Mantravadi J, Kotylo PK, Mullins R, Walker S, Roth LM. Proliferative activity and aneuploidy in pleomorphic adenomas of the salivary glands. Arch Pathol Lab Med 1994;118:252-9.
  43. Sunardhi-Widyaputra S, van den Oord JJ, van Houdt K, Ley MD, Van Damme B. Identification of metallothionein- and parathyroid hormone-related peptide (PTHrP)-positive cells in salivary gland tumours. Path Res Pract 1995;191:1092-8. Go to original source... Go to PubMed...